ARCHIVES

Reviewers Note Major Flaws In Design Of Burzynski’s Trials

This article is from The Cancer Letter archive.

Vol. 24 No. 36 | September 25, 1998

Download PDF Visit The Full Archive

Related Articles

Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation

June 29, 2012

A Biostatistics Paper Alleges Potential Harm To Patients In Two Duke Clinical Studies

October 2, 2009

Herceptin Lowers Recurrence In Early Breast Cancer

November 25, 2005

Program Announcements

July 25, 1986

Consensus Conference Suggest Research Required For Advances In Pain Control

May 30, 1986

Gene Expression Data Posted On Web For Research Use.

March 17, 2000